title: ERBB2 inhibition and heart failure.
authors.affiliation: Massachusetts General Hospital Cancer Center, Boston, USA.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Cote
authors.forename: Douglas B
authors.initials: DB
authors.lastname: Sawyer
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Chabner
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D020890:Neuregulin-1 / Q000032:analysis / Q000378:metabolism / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015415:Biomarkers; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human